JP7394065B2 - ボルデテラ属種を培養する方法 - Google Patents
ボルデテラ属種を培養する方法 Download PDFInfo
- Publication number
- JP7394065B2 JP7394065B2 JP2020550857A JP2020550857A JP7394065B2 JP 7394065 B2 JP7394065 B2 JP 7394065B2 JP 2020550857 A JP2020550857 A JP 2020550857A JP 2020550857 A JP2020550857 A JP 2020550857A JP 7394065 B2 JP7394065 B2 JP 7394065B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- bordetella
- liquid medium
- species
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000588807 Bordetella Species 0.000 title claims description 57
- 239000002253 acid Substances 0.000 claims description 159
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 86
- 238000000034 method Methods 0.000 claims description 80
- 239000007788 liquid Substances 0.000 claims description 76
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 68
- 229910017604 nitric acid Inorganic materials 0.000 claims description 68
- 108010021711 pertactin Proteins 0.000 claims description 67
- 239000000427 antigen Substances 0.000 claims description 63
- 108091007433 antigens Proteins 0.000 claims description 63
- 102000036639 antigens Human genes 0.000 claims description 63
- 241001135529 Bordetella sp. Species 0.000 claims description 50
- 101100446590 Arabidopsis thaliana FIM5 gene Proteins 0.000 claims description 47
- 101150106011 FIM2 gene Proteins 0.000 claims description 47
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 43
- 150000007513 acids Chemical class 0.000 claims description 43
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 41
- 101710154643 Filamentous hemagglutinin Proteins 0.000 claims description 36
- 239000012134 supernatant fraction Substances 0.000 claims description 36
- 238000012258 culturing Methods 0.000 claims description 29
- 241000588832 Bordetella pertussis Species 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 241000894007 species Species 0.000 claims description 10
- 229940031626 subunit vaccine Drugs 0.000 claims description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 239000001116 FEMA 4028 Substances 0.000 claims description 4
- 229960004853 betadex Drugs 0.000 claims description 4
- 101710186708 Agglutinin Proteins 0.000 claims description 3
- 101710146024 Horcolin Proteins 0.000 claims description 3
- 101710189395 Lectin Proteins 0.000 claims description 3
- 101710179758 Mannose-specific lectin Proteins 0.000 claims description 3
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims description 3
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims description 3
- 239000000910 agglutinin Substances 0.000 claims description 3
- 239000002609 medium Substances 0.000 description 94
- 239000000243 solution Substances 0.000 description 66
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 62
- 210000004027 cell Anatomy 0.000 description 60
- 239000006228 supernatant Substances 0.000 description 51
- 235000011007 phosphoric acid Nutrition 0.000 description 47
- 239000000203 mixture Substances 0.000 description 27
- 229960005486 vaccine Drugs 0.000 description 26
- 150000007522 mineralic acids Chemical class 0.000 description 19
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 18
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000003306 harvesting Methods 0.000 description 11
- 239000003102 growth factor Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- -1 ammonium ions Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 238000011218 seed culture Methods 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 239000002518 antifoaming agent Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 201000005702 Pertussis Diseases 0.000 description 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003016 phosphoric acids Chemical class 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000588779 Bordetella bronchiseptica Species 0.000 description 2
- 241000588780 Bordetella parapertussis Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 2
- 238000013494 PH determination Methods 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241001510071 Pyrrhocoridae Species 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 2
- 229940005991 chloric acid Drugs 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 229960003983 diphtheria toxoid Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 239000004223 monosodium glutamate Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229940066827 pertussis vaccine Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000588851 Bordetella avium Species 0.000 description 1
- 241001477981 Bordetella hinzii Species 0.000 description 1
- 241001495147 Bordetella holmesii Species 0.000 description 1
- 241000543043 Bordetella trematum Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101150048576 FIM3 gene Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000012365 batch cultivation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 229940077239 chlorous acid Drugs 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000012444 downstream purification process Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- CUILPNURFADTPE-UHFFFAOYSA-N hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000035040 seed growth Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010046845 tryptones Proteins 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/72—Undefined extracts from bacteria
Description
本出願は、米国仮特許出願第62/645,473号(2018年3月20日出願)(その開示全体が参照により本明細書に加入される)の利益を主張し、その出願日に依る。
本出願は、概して、百日咳菌(Bordetella pertussis)のようなボルデテラ属種(Bordetella species)を培養するための方法に関する。
百日咳は、重篤な咳き込みを特徴とする肺の細菌感染症である。百日咳菌(Bordetella pertussis)は、この状態の主原因である。化学的に解毒された百日咳菌(B.pertussis)の全細胞(wP)を含み、そしてジフテリア及び破傷風抗原とともに製剤化されたワクチンが何十年も利用可能である。1990年代から、wPワクチンは多くの国において無細胞百日咳ワクチンと置き換えられてきた。無細胞百日咳(aP)ワクチンは、wPワクチンと比較して比較的少ない副作用を誘導し、これらは発熱の高い危険性、注射部位での反応源性及びより少ない程度でけいれんを伴う。
グルタメート+NAD++H2O=NH4 ++NADH+H++α-ケトグルタレート
本発明者らは、上清中の増加した量のPRNを生じる、ボルデテラ属種を培養するための方法を開発した。驚くべきことに、本発明者らは、上清中のPRNの量が、少なくとも部分的に、培養の間pHを維持するために使用される酸の種類に依存するということに気づいた。さらに、本発明者らは、驚くべきことに、pH制御のために特定の酸ブレンドを使用することにより他の抗原の収量に影響を及ぼすことなく上清中でPRNを増加させることができるということに気づいた。さらに、本発明者らは、強い酸又は酸ブレンドの使用がバイオマスレベルでの実質的な変化を生じないということを発見した。従って、pH制御のために使用される酸の種類の単純な変化が、下流ボルデテラ抗原製造プロセスに対して最小の影響を生じる。本方法のこれら及び他の予期せぬ利益は本明細書以下に記載される。
様々な望ましい局面の以下の記載は、本来は単に例示に過ぎず、そしていかなるようにも本開示、その適用、又は使用を制限することは意図されない。
様々な実施態様において、液体培地のpHは、生物の培養の間継続的に評価され、そして必要に応じて、生物の増殖の間、値の所定の範囲内に培地のpHを維持するために十分な濃度で、酸が液体培地に供給される。一般に、培養全体を通して培地が制御されるpHの範囲は、典型的には、約6.0~約9.0、より典型的には約6.8~約7.3、例えば、約7.0~7.2である。pHの決定、及び必要な場合調整は、典型的には自動で、例えばポンプに作動可能に接続されたpHメーターを使用して自動的に達成され、このポンプは、所定の範囲外のpH決定に応じて、液体培地に酸をポンプで送るための蠕動ポンプであり得る。
本開示はまた、本明細書に記載されるように、ボルデテラ属種を培養するための方法に関し、該方法は:ボルデテラ属種を液体培地中にて本明細書に記載されるように有酸素条件下で培養すること;及び該種の培養の間、液体培地のpHを維持することを含み、ここで液体培地のpHを維持することは:該ボルデテラ属種の培養の間に、本明細書に記載されるpH値の所定の範囲内に液体培地のpHを維持するために必要に応じて培地に第一及び第二の酸を添加することを含み、ここで該第一の酸は、水中で本質的に完全に解離する無機酸であり、そしてここで該第二の酸は、1より大きい酸解離定数(pKa)を有する無機酸又は有機酸である。
いくつかの実施態様において、本明細書に記載される単離された抗原の1つ又はそれ以上は、免疫原性組成物又はサブユニットワクチンに製剤化される。本明細書で使用される「サブユニットワクチン」は、目的の病原体、例えば、ウイルス、細菌、寄生生物、真菌、又は真菌様生物から誘導されるか、それらと相同であるか、又はそれら由来の(全ての抗原ではないが)1つ又はそれ以上の抗原を含むワクチンの型を指す。このようなワクチンは、インタクトな病原細胞もしくは病原性粒子、又はそのような細胞もしくは粒子の溶解物も実質的に含まない。従って、サブユニットワクチン又はサブユニット組成物は、病原体から少なくとも部分的に精製されたか、又は実質的に精製された免疫原性ポリペプチド又はそれらのアナログから製造され得る。サブユニットワクチンにおける抗原を得る方法としては、標準的な精製技術、組み換え産生、又は化学合成が挙げられる。従って「サブユニットワクチン」は、ウイルス、細菌、又は他の免疫原の規定された抗原性成分からなるワクチンを指す。
100x増殖因子溶液(表4)5mLを含むブロス(改変Stainer-Scholte培地、表3)500mLをそれぞれ入れた2L振盪フラスコにおいて作業シード(2.5mL)を播種した。培養物を44時間インキュベーター振盪機で増殖させ、そして増殖因子溶液(表4)を追加したブロス1150mL(改変Stainer-Scholte培地、表3)を入れた2L発酵器/バイオリアクター(2L BIOSTAT B発酵器(B.Braun Biotech International、Berlin、Germany)に播種するために使用した。
Claims (15)
- ボルデテラ属種を培養する方法であって、該方法は:
ボルデテラ属種を液体培地中にて有酸素条件下で培養すること;及び
該種の培養の間、液体培地のpHを維持することを含み、ここで液体培地のpHを維持することは:
該ボルデテラ属種の培養の間にpH値の所定の範囲内に液体培地のpHを維持するために液体培地に第一及び第二の酸を添加することを含み、
ここで該第一の酸は、硝酸であり、
ここで該第二の酸は、リン酸であり、
ここで第一の酸及び第二の酸は溶液状態で混合され、該溶液は、第一の酸を30%~50%及び第二の酸を50%~70%(%体積/体積)含み、第一の酸の濃度は、3.5Mであり、第二の酸の濃度は、2.5Mであり、そして
ここで上記pH値の所定の範囲は6.0~9.0である、
上記方法。 - 該溶液は、第一の酸40%及び第二の酸60%(体積/体積)を含む、請求項1に記載の方法。
- 上記方法は、液体培地からボルデテラ抗原を単離することをさらに含む、請求項1又は2に記載の方法。
- ボルデテラ抗原を単離することは:
ボルデテラ属種の培養後に液体培地を細胞フラクション及び上清フラクションに分離すること;
百日咳毒素(PT)、繊維状赤血球凝集素(FHA)及びパータクチン(PRN)の1つ又はそれ以上を上清フラクションから単離すること、並びに
2型及び3型線毛を細胞フラクションから単離すること
を含む、請求項3に記載の方法。 - 上記方法は、単離された抗原をサブユニットワクチンとして製剤化することを更に含む
、請求項4に記載の方法。 - ボルデテラ属種を培養する方法であって、該方法は:
ボルデテラ属種を有酸素条件下で液体培地中にて培養すること;及び液体培地のpHを該種の培養の間維持することを含み、ここで液体培地のpHを維持することは:
該ボルデテラ属種の培養の間pH値の所定の範囲内に液体培地のpHを維持するために液体培地に硝酸を添加することを含み、
ここで上記pH値の所定の範囲は6.0~9.0である、
上記方法。 - 上記方法は、液体培地からボルデテラ抗原を単離することをさらに含む、請求項6に記載の方法。
- ボルデテラ抗原を単離することは:
ボルデテラ属種の培養後に液体培地を細胞フラクション及び上清フラクションに分離すること;
ボルデテラ抗原を上清フラクションから単離することを含み、ここで単離されたボルデテラ抗原はパータクチンを含む、請求項7に記載の方法。 - 上記方法は、単離されたボルデテラ抗原をサブユニットワクチンとして製剤化することをさらに含む、請求項7又は8に記載の方法。
- ボルデテラ属種培養からの上清フラクションにおけるボルデテラ線毛性凝集原2及び線毛性凝集原3(FIM2/3)の収量を増加させるための方法であって、該方法は:
ボルデテラ属種を有酸素条件下で液体培地中にて培養すること;
該種の培養の間、液体培地のpHを維持することであって、ここで液体培地のpHを維持することは:
該ボルデテラ属種の培養の間、pH値の所定の範囲内に液体培地のpHを維持するために液体培地に酸を添加することを含み、
ここで酸は硝酸を含む;
ボルデテラ属種培養後に液体培地を細胞フラクション及び上清フラクションに分離すること;並びに
上清フラクションからFIM2/3を単離すること
を含み、
ここで上記pH値の所定の範囲は6.0~9.0である、
上記方法。 - 上記ボルデテラ属種は百日咳菌である、請求項1~10のいずれか1項に記載の方法。
- 上記pH値の所定の範囲は6.8~7.3である、請求項1~11のいずれか1項に記載の方法。
- 上記ボルデテラ属種の培養は大規模製造条件下で起こる、請求項1~12のいずれか1項に記載の方法。
- 液体培地は化学的に規定された液体培地である、請求項1~13のいずれか1項に記載の方法。
- 上記化学的に規定された液体培地は、ジメチル-β-シクロデキストリンを追加されたStainer-Scholte培地である、請求項14に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862645473P | 2018-03-20 | 2018-03-20 | |
US62/645,473 | 2018-03-20 | ||
PCT/IB2019/000305 WO2019180507A1 (en) | 2018-03-20 | 2019-03-19 | Methods of cultivating bordetella species |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021518148A JP2021518148A (ja) | 2021-08-02 |
JP7394065B2 true JP7394065B2 (ja) | 2023-12-07 |
Family
ID=67986778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020550857A Active JP7394065B2 (ja) | 2018-03-20 | 2019-03-19 | ボルデテラ属種を培養する方法 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3768821A4 (ja) |
JP (1) | JP7394065B2 (ja) |
CN (1) | CN112513248A (ja) |
WO (1) | WO2019180507A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023190829A1 (ja) * | 2022-03-31 | 2023-10-05 | 富士フイルム株式会社 | 生産物の製造方法、及び生産物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008146830A1 (ja) | 2007-05-28 | 2008-12-04 | The Kitasato Institute | パラ百日咳菌全菌体ワクチン組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE134194T1 (de) * | 1989-11-06 | 1996-02-15 | Smithkline Beecham Biolog | Verfahren |
CA2138178A1 (en) * | 1993-12-22 | 1995-06-23 | Andrew Herbert | Control of ph during bordetella growth |
-
2019
- 2019-03-19 CN CN201980032472.6A patent/CN112513248A/zh active Pending
- 2019-03-19 WO PCT/IB2019/000305 patent/WO2019180507A1/en unknown
- 2019-03-19 JP JP2020550857A patent/JP7394065B2/ja active Active
- 2019-03-19 EP EP19771590.7A patent/EP3768821A4/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008146830A1 (ja) | 2007-05-28 | 2008-12-04 | The Kitasato Institute | パラ百日咳菌全菌体ワクチン組成物 |
Non-Patent Citations (1)
Title |
---|
日本細菌学雑誌, 1996, Vol. 51, No. 3, pp. 737-744 |
Also Published As
Publication number | Publication date |
---|---|
JP2021518148A (ja) | 2021-08-02 |
EP3768821A1 (en) | 2021-01-27 |
EP3768821A4 (en) | 2022-03-30 |
US20200407678A1 (en) | 2020-12-31 |
WO2019180507A1 (en) | 2019-09-26 |
CN112513248A (zh) | 2021-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9707286B2 (en) | Process for detergent-free production of outer membrane vesicles of a gram-negative bacterium | |
JP4917087B2 (ja) | ジフテリア毒素生産のための発酵方法 | |
EP0914153B1 (en) | Multivalent dtp-polio vaccines | |
CN1198099A (zh) | 非菌体性百日咳疫苗及其制备方法 | |
JP6582020B2 (ja) | 発酵方法 | |
JP6347778B2 (ja) | ヘモフィルス・インフルエンザb型菌抗原の生成方法 | |
CN1915424A (zh) | 非菌体性百日咳疫苗及其制备方法 | |
JP7394065B2 (ja) | ボルデテラ属種を培養する方法 | |
JP3035712B2 (ja) | 新規なワクチンおよびそのための方法 | |
US11970690B2 (en) | Methods of cultivating Bordetella species | |
JP6385441B2 (ja) | ボルデテラ属種の工業規模培養のための合成培地 | |
ES2775209T3 (es) | Procedimiento de determinación del contenido de endotoxinas en una preparación de sal de aluminio | |
Bronzino et al. | Vaccine Production | |
JP2022502469A (ja) | 低減用量の不活化ポリオウイルスを含む混合ワクチン組成物およびそれを調製するための方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220308 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230501 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230725 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231020 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231114 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231127 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7394065 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |